# Seroba Life Sciences

> Seroba Life Sciences is a VC fund backing Health Care and Biotechnology. See 48 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Dublin, Ireland
- Total investments: 48
- Last investment: May 2025
- Lead investor: 35%
- Fund size: $111M
- Last fund: Feb 2017
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/serobalifesciences/
- Website: http://www.seroba-lifesciences.com/

Seroba Life Sciences is a VC fund in Dublin focused on Health Care and Biotechnology. Seroba is a life sciences venture capital firm, focused on investing in breakthrough healthcare technologies that promise to improve lives and make a difference worldwide.Headquartered in Ireland, the firm works with some of the world’s best entrepreneurs developing innovative medical devices, diagnostics, and therapeutic drugs. It funds newhealthcare opportunities through key value-adding stages, assisting its invested companies from inception through development and clinical evaluation, the generation of intellectual property, regulatory approvals and market launch, and partnering with leading pharmaceutical or medtech companies.The Seroba team combines in-depth scientific and medical knowledge with broad regulatory and commercial expertise. They are known for patience, understanding, commitment and passion, well-demonstrated by the caliber of entrepreneurs they back, and an overriding focus on delivering improvements to people's lives and value to their stakeholders.

## Contacts

5 contacts available for Seroba Life Sciences. Shizune tracks 9 team members at Seroba Life Sciences. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/seroba-life-sciences?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.4M–$33M |
| Series B | $4.6M–$105M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 20 | 42% |
| Biotechnology | 18 | 38% |
| Medical | 15 | 31% |
| Medical Device | 10 | 21% |
| Therapeutics | 8 | 17% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 17 | 35% |
| Series B | 16 | 33% |
| Funding Round | 6 | 13% |
| Series C | 2 | 4% |
| Series D | 2 | 4% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Ireland | 9 | 19% |
| United States | 7 | 15% |
| United Kingdom | 6 | 13% |
| The Netherlands | 3 | 6% |
| Switzerland | 2 | 4% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alan O'Connell | Partner | 7 | https://shizune.co/investors/profile/alan-oconnell |
| Bruno Montanari | Partner | 5 | https://shizune.co/investors/profile/bruno-montanari |
| Daniel O' Mahony | Partner | 6 | https://shizune.co/investors/profile/daniel-o-mahony |
| Seamus O’Hara | Director | 0 | https://shizune.co/investors/profile/seamus-ohara |
| Andrew Duignan | CFO | 0 | https://shizune.co/investors/profile/andrew-duignan |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Azafaros | Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $147.6M | Series B | May 13, 2025 |  |
| Perfuze | Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway. | $23.9M |  | Mar 13, 2025 |  |
| Coave Therapeutics | Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $32.9M | Series A | Jan 09, 2025 |  |
| Deciphex | Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $32.1M | Series C | Jan 07, 2025 |  |
| ShiraTronics | ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device acceleratorcompany. | $66M | Series B | Sep 30, 2024 |  |
| Ryme Medical | Ryme Medical is a company that develops therapies aimed at treating individuals suffering from chronic bronchitis and emphysema. The organization focuses on addressing chronic obstructive pulmonary disease by targeting the sympathetic nervous system, mitigating its effects, and alleviating the distress of those who struggle to breathe. Thisapproach allows patients to receive improved treatment and breathe with greater ease. |  | Series A | Aug 21, 2024 |  |
| Loci Orthopaedics | The InDx implant is the only implant that can fully mimic the natural but complex motions of the thumb joint. The device is also easier to insert and less invasive than any currently available surgical treatment option for this condition. | $14M | Series A | Jul 17, 2024 |  |
| Vico Therapeutics | Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $12.3M | Series B | Jun 24, 2024 |  |
| Artica Therapeutics | Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food. | $12.7M | Seed | Nov 02, 2023 |  |
| Shorla Pharma | Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact. | $35M | Series B | Oct 04, 2023 |  |

10 of 48 investments shown.

## Co-investors
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund, 7 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 6 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 6 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 5 deals together
- [Atlantic Bridge](https://shizune.co/investors/profile/atlantic-bridge) — VC Fund, 4 deals together
- [b2venture](https://shizune.co/investors/profile/btovpartners) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)
- [All Investors in Ireland](https://shizune.co/investors/investors-ireland)
- [All VC Funds in Ireland](https://shizune.co/investors/vc-funds-ireland)
- [Transportation VC Funds in Ireland](https://shizune.co/investors/transportation-vc-funds-ireland)
- [Biotech Investors in Ireland](https://shizune.co/investors/biotech-investors-ireland)

## FAQ

### What does Seroba Life Sciences invest in?

Seroba Life Sciences invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 48 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Seroba Life Sciences's check size?

Seroba Life Sciences typically joins rounds of $5.4M–$33M at Series A and $4.6M–$105M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Seroba Life Sciences participates in.

### How do I contact Seroba Life Sciences?

Public channels for Seroba Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Seroba Life Sciences?

The team at Seroba Life Sciences includes Alan O'Connell (Partner), Bruno Montanari (Partner) and Daniel O' Mahony (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co